Patton Fund Management Inc. Boosts Holdings in CVS Health Corporation $CVS

Key Points

• Patton Fund Management boosted its position in CVS by 42.7% in Q4, buying an additional 27,699 shares to hold 92,510 shares valued at about $7.34 million.
• CVS beat Q4 estimates with EPS $1.09 (vs. $1.00) and revenue of $105.69 billion, and issued FY2026 guidance of 5.94–6.14 EPS, roughly matching analysts' consensus near 5.89.
• CVS declared a quarterly dividend of $0.665 (annualized $2.66, ~3.4% yield), though its payout ratio is elevated at about 192.75%.

Patton Fund Management Inc. lifted its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 42.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 92,510 shares of the pharmacy operator's stock after buying an additional 27,699 shares during the period. Patton Fund Management Inc.'s holdings in CVS Health were worth $7,342,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Assetmark Inc. grew its position in CVS Health by 8.0% during the 4th quarter. Assetmark Inc. now owns 732,669 shares of the pharmacy operator's stock worth $58,145,000 after purchasing an additional 54,111 shares during the last quarter. Third View Private Wealth LLC purchased a new position in CVS Health during the 4th quarter worth $2,769,000. Legacy Bridge LLC grew its position in CVS Health by 8.1% during the 4th quarter. Legacy Bridge LLC now owns 1,918 shares of the pharmacy operator's stock worth $152,000 after purchasing an additional 143 shares during the last quarter. FSM Wealth Advisors LLC grew its position in CVS Health by 2.9% during the 4th quarter. FSM Wealth Advisors LLC now owns 10,495 shares of the pharmacy operator's stock worth $833,000 after purchasing an additional 292 shares during the last quarter. Finally, ABLE Financial Group LLC grew its position in CVS Health by 9.3% during the 4th quarter. ABLE Financial Group LLC now owns 45,045 shares of the pharmacy operator's stock worth $3,575,000 after purchasing an additional 3,818 shares during the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Down 1.5%

Shares of NYSE:CVS opened at $78.12 on Tuesday. The company has a market cap of $100.12 billion, a price-to-earnings ratio of 56.61, a PEG ratio of 0.83 and a beta of 0.51. CVS Health Corporation has a fifty-two week low of $58.35 and a fifty-two week high of $85.15. The firm's 50-day simple moving average is $75.97 and its 200-day simple moving average is $77.83. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping analysts' consensus estimates of $1.00 by $0.09. The firm had revenue of $105.69 billion for the quarter, compared to the consensus estimate of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm's revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, equities research analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Investors of record on Thursday, April 23rd will be issued a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 3.4%. CVS Health's payout ratio is currently 192.75%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Piper Sandler lowered their price objective on shares of CVS Health from $101.00 to $99.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 31st. Argus lowered their price objective on shares of CVS Health from $91.00 to $90.00 and set a "buy" rating on the stock in a research report on Wednesday, January 28th. Bank of America lowered their target price on shares of CVS Health from $100.00 to $95.00 and set a "buy" rating on the stock in a report on Tuesday, January 27th. Leerink Partners reaffirmed an "outperform" rating and issued a $98.00 target price on shares of CVS Health in a report on Thursday, March 5th. Finally, The Goldman Sachs Group lifted their target price on shares of CVS Health from $95.00 to $97.00 and gave the company a "buy" rating in a report on Thursday, February 12th. Twenty research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and a consensus price target of $94.95.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.